REGENXBIO Announces RGX-314 Data Presentations at American Society of Retina Specialists Annual Meeting
- Data for Cohort 1 with three months of follow-up from the RGX-314 Phase II trial for the treatment of diabetic retinopathy (ALTITUDE®) to be presented
Title: Suprachoroidal Delivery of RGX-314 for Diabetic Retinopathy Without CI-DME: Early Results From the Phase II ALTITUDE Study
Presenter: Dennis Marcus, M.D., F.A.S.R.S., Southeast Retina Center
Session Title: Diabetic Retinopathy 2 Symposium
Date/Time: Saturday, October 9, 2021, from
Type: Oral presentation
Title: Subretinal Delivery of RGX-314 for Neovascular AMD: End of Study Phase I/IIa Results (Encore Presentation)
Presenter: Lejla Vajzovic, M.D., F.A.S.R.S., Surgical & Medical Retina Specialist & Director of Duke Eye Center Continuing Medical Education
Session Title: Wet AMD 1 Symposium
Date/Time: Monday, October 11, 2021, from
Type: Oral presentation
Title: Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study (Encore Presentation)
Presenter: Mark Barakat, M.D., F.A.S.R.S., Director of Research,
Session Title: Wet AMD 1 Symposium
Date/Time: Monday, October 11, 2021, from
Type: Oral presentation
About RGX-314
RGX-314 is being investigated as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal conditions. RGX-314 consists of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF). RGX-314 is believed to inhibit the VEGF pathway by which new, leaky blood vessels grow and contribute to the accumulation of fluid in the retina.
About REGENXBIO Inc.
SCS Microinjector® is a trademark of Clearside Biomedical, Inc. All other trademarks referenced herein are registered trademarks of
Contacts:
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
brendan@argotpartners.com
Media:
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-rgx-314-data-presentations-at-american-society-of-retina-specialists-annual-meeting-301389567.html
SOURCE